About Code Biotherapeutics
Code Biotherapeutics is a company based in Hatfield (United States) founded in 2020 by Robert C Getts. Code Biotherapeutics has raised $85 million across 2 funding rounds from investors including Amgen, UPMC and Takeda Pharmaceuticals. Code Biotherapeutics offers products and services including 3DNA Platform. Code Biotherapeutics operates in a competitive market with competitors including BridgeBio, Spark Therapeutics, Alnylam, ATAI and Insitro, among others.
- Headquarter Hatfield, United States
- Founders Robert C Getts
- SectorsHealthcare
- Email••••••••
- Website codebiotx.com
- Social LinkedIn X
- Total Equity Funding$85M (USD)
in 2 rounds
- Latest Funding Round$75M (USD), Series A
Jun 2022
- InvestorsAmgen
& 11 more
Products & Services of Code Biotherapeutics
Code Biotherapeutics offers a comprehensive portfolio of products and services, including 3DNA Platform.
Enables targeted delivery of genetic medicines to overcome toxicity and targeting issues.
Funding Insights of Code Biotherapeutics
Code Biotherapeutics has successfully raised a total of $85M across 2 strategic funding rounds. The most recent funding activity was a Series A round of $75 million completed in June 2022. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $85M
- Total Rounds 2
- Last Round Series A — $75M
- First Round $10M
(Apr 2021)
- Investors Count 12
All 2 funding rounds of Code Biotherapeutics with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jun 2022 | $75M | Series A | – | Northpond Ventures | |
| Apr 2021 | $10M | Seed | – | 4Bio Capital, UPMC |
12 investors in total: 12 institutional.
Investors in Code Biotherapeutics
Code Biotherapeutics has secured backing from 12 investors, including venture fund and institutional investors. Prominent investors backing the company include Amgen, UPMC and Takeda Pharmaceuticals.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Venture capital firm investing in life sciences & tech sectors | – | npv.vc | Cambridge, United States | |
UCB Ventures is focused on strategic corporate venture investments. | 2017 | ucbventures.com | Brussels, Belgium | |
- | – | 4biocapital.com | - | |
Tech & Life Sciences focused VC firm investing in early stage companies in the US & Europe | – | hatterasvp.com | Durham, United States | |
Venture capital investments are offered to startups by NEA. | – | nea.com | Menlo Park, United States | |
Companies developing T1D products are funded through venture philanthropy. | – | t1dfund.org | Boston, United States | |
Takeda Pharmaceuticals is engaged in developing innovative medicines globally. | 1781 | takeda.com | Tokyo, Japan | |
Developer of pharmaceutical products for treating multiple diseases | 1980 | amgen.com | Thousand Oaks, United States | |
Genetic disorder treatments and care services are supported through ventures. | 2014 | cureduchenne.org/ventures | Newport Beach, United States | |
Health care innovations are developed and commercialized by UPMC Enterprises. | – | enterprises.upmc.com | Pittsburgh, United States |
Investor details for Code Biotherapeutics
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Code Biotherapeutics
20 people are tracked at Code Biotherapeutics (8 in leadership, 9 in board & advisors, 3 in team).
| Name | Role | Group |
|---|---|---|
Robert C Getts | Co-Founder & CTO | Leadership |
Alex T. | Chief Technical Officer | Leadership |
Brian P. McVeigh | CEO | Leadership |
Alexander Tracy | CTO | Leadership |
Keith G. Dewedoff | Chief Financial Officer | Leadership |
Matthew Roberts | Head of Analytical Methods Development | Leadership |
Paula Carpenter | Head Of Program Management And Production | Leadership |
Vidyullatha Vasireddy | Head Of Translational Medicine | Leadership |
Kathy R. | Non Executive Director | Board & advisors |
James Bauersmith | Director | Board & advisors |
Russ Fein | Director | Board & advisors |
Dima Kuzmin | Director | Board & advisors |
Jason Baranski | Director | Board & advisors |
Diana Bernstein | Board Director | Board & advisors |
Ed Mathers | Director | Board & advisors |
Kathy Rouan | Independent Director | Board & advisors |
Joseph Truitt | Lead Independent Director | Board & advisors |
Patricia Holt | Legal Affairs Lead | Team |
Samantha Brown | Research Scientist | Team |
Sai Abhishek | Strategy & Business Development | Team |
Complete people profiles for Code Biotherapeutics
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of Code Biotherapeutics
3 dated milestones of Code Biotherapeutics across 2 years, from founding to its latest funding, stage changes and deals.
- Founded Code Biotherapeutics is founded.
- Funding First funding round of $10.0M.
- Funding Latest funding round, Series A, of $75.0M.
Competitors of Code Biotherapeutics
Code Biotherapeutics operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as BridgeBio, Spark Therapeutics, Alnylam, ATAI and Insitro, among others.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| bridgebio.com | 2015 | Palo Alto, United States | $434.2M | – | Therapeutics for genetic diseases are developed through targeted interventions. | |
| sparktx.com | 2013 | Philadelphia, United States | $82.8M | 822 | Gene therapies for rare diseases including retinal dystrophies are developed. | |
| alnylam.com | 2002 | Cambridge, United States | $17M | 2,100 | RNA interference-based therapeutics are developed for multiple disorders. | |
| atai.life | 2018 | Munich, Germany | $386.67M | – | A biopharmaceutical company accelerating innovative mental health treatments. | |
| insitro.com | 2018 | San Francisco, United States | $643.21M | 257 | An AI-enabled platform is developed for infectious disease treatment. | |
| ultragenyx.com | 2010 | Novato, United States | $135.1M | 837 | Therapeutics for rare and ultra-rare metabolic diseases are developed. | |
| forgebiologics.com | 2020 | Columbus, United States | $250M | 118 | Gene therapies for rare diseases are developed to treat patients. | |
| chimerix.com | 2002 | Durham, United Kingdom | $95.23M | 72 | Antiviral oral therapeutics are developed for infectious diseases and cancers. | |
| cariboubio.com | 2011 | Berkeley, United States | $156.55M | 92 | Provider of cell therapies to treat cancer and hematologic conditions |
Detailed competitors of Code Biotherapeutics
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Code Biotherapeutics
The website of Code Biotherapeutics (codebiotx.com) receives about 1K visits a month.
- Monthly visits1K
▼ 60.2% vs previous month
Latest news on Code Biotherapeutics
Complete news archive for Code Biotherapeutics
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Similar companies to Code Biotherapeutics
10 companies that operate in the same segment as Code Biotherapeutics (Genomics & Gene Therapy Platforms), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Digital sequencing technology for cancer detection is developed. | 2012 | Redwood City, California, United States | USD 557.5 M | USD 982.02 M | 2,020 | |
Circulating tumor DNA is screened for early cancer detection. | 2016 | Menlo Park, California, United States | USD 3.22 B | USD 147.17 M | 1,000 | |
Nanopore-based electronic systems for single-molecule analysis are developed. | 2005 | Oxford, Oxfordshire, United Kingdom | USD 1.3 B | USD 301.49 M | 1,480 | |
Provider of genetic test solutions to study ancestry, genealogy, and inherited traits | 2006 | Sunnyvale, California, United States | USD 943.53 M | USD 189.9 M | 265 | |
Provider of DNA testing services to create a family tree and ancestor | 2003 | Yehud, Central District, Israel | USD 40 M | – | – | |
Genetically modified cell lines are developed using AAV gene-editing platform. | 2007 | Cambridge, Cambridgeshire, United Kingdom | USD 46.29 M | – | – | |
Gene therapies for rare diseases including retinal dystrophies are developed. | 2013 | Philadelphia, Pennsylvania, United States | USD 82.8 M | USD 64.73 M | 822 | |
Therapeutics for genetic diseases are developed through targeted interventions. | 2015 | Palo Alto, California, United States | USD 434.2 M | USD 502.08 M | 730 | |
Provider of an online genealogy platform offering a host of services | 1996 | Lehi, Utah, United States | USD 146.2 M | – | – |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about Code Biotherapeutics
Code Biotherapeutics was founded in 2020 and raised its 1st funding round 1 year after it was founded.
Code Biotherapeutics is headquartered in Hatfield, United States.
Code Biotherapeutics is a funded company, having raised a total of $85M across 2 funding rounds to date. The company's 1st funding round was a Seed of $10M, raised on Apr 2021.
Founded in 2020, Code Biotherapeutics operates in the biotechnology sector, focusing on gene therapies for rare conditions such as Duchenne muscular dystrophy and type 1 diabetes. A proprietary non-viral platform, 3DNA, is utilized to deliver genes of varying sizes, enhance cellular targeting, and minimize immunogenicity. The company is based in Hatfield, United States, with efforts centered on advancing these treatments through research and development.
Code Biotherapeutics's top competitors include Spark Therapeutics, BridgeBio and Forge Biologics.
Code Biotherapeutics offers 3DNA Platform.
Code Biotherapeutics has 12 investors. Key investors include Amgen, UPMC, Takeda Pharmaceuticals, CureDuchenne Ventures, and Northpond Ventures.